Biogen Idec, Fumapharm's multiple sclerosis drug reduces brain lesions, study says

By Angela McDaniels

Seattle, Jan. 9 - Biogen Idec and Fumapharm AG said a phase 2 study designed to evaluate the efficacy and safety of its investigational drug BG-12 in patients with relapsing-remitting multiple sclerosis met its primary endpoint.

Treatment with BG-12 led to a statistically significant reduction in the total number of gadolinium-enhancing brain lesions in patients with six months of treatment, the companies said in a news release.

The multi-center, double-blind, placebo-controlled study enrolled 250 patients at sites in 10 European countries.

Cambridge, Mass.-based Biogen Idec develops targeted immunotherapies for cancer, autoimmune diseases and inflammatory diseases.

Fumapharm is a privately held pharmaceutical company based in Lucerne, Switzerland, that has licensed exclusive, worldwide development and marketing rights for BG-12 to Biogen Idec.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.